PersonaDx

At PersonaDx, we are redefining cancer care by harnessing molecular genetics and clinical risk factors with a clinically validated neural network. Our mission is to advance the predictive and therapeutic landscape in oncology, providing unmatched accuracy in cancer prognosis. We are actively seeking partnerships in various areas, including pharmaceutical companies, research institutions, genomic sequencing labs, and healthcare providers. Join us in our mission to transform cancer therapy and improve patient outcomes worldwide. PersonaDx integrates molecular genetics and clinical data powered by AI to revolutionize cancer prognosis, delivering unmatched accuracy in predicting recurrence and optimizing treatment plans for metastatic tumors. With a clinically validated 96% accuracy rate, PersonaDx sets a new standard in precision medicine. Metastasis-Centric Approach Defines integrated risk groups that are highly prognostic for survival after treatment. Precision-Driven Decisions Accurate, data-driven therapeutic recommendations leveraging genomics and clinical data. Superior Treatment Predictions Informs personalized treatment based on the identified phenotype of the metastasis. Innovative Products - Persona31g & Persona150gz: Advanced subtyping tools with proprietary biomarkers. - PersonaAI: AI-driven platform advising the clinical team throughout the care path. Key Highlights - 96% accuracy of 31-feature neural network. - Enhanced Survival Rates: Significant increases with biomarker-informed predictions. 5-year OS of 30-90% versus current coin flip. - Proven Success: Phase 3 New-EPOC trial shows superior predictive power. - 25% Exceptional Outcomes: Patients achieve excellent survival/cure after treatment. Join us in transforming cancer therapy and improving patient outcomes worldwide. Discover how PersonaDx can transform cancer prognostics and treatment. Contact us to learn more at [email protected].

Website

persona-dx.com

External link for PersonaDx

Industry

Hospitals and Health Care

Company size

2-10 employees

Headquarters

Chicago, Illinois

Type

Privately Held

Founded

2022

Specialties

Metastatic Cancer, Diagnosis, Radiotherapy, Immunotherapy, Cancer, Biotechnology, Genetic Sequencing, AI-Powered Cancer Prognosis, Cancer Prognosis, Metastatic Cancer Prognosis, Precision Medicine, Personalized Medicine, Personalized Cancer Prognosis, Precision Oncology, Metastatic Tumor, Genomic Sequencing, Precision Oncology Solutions, AI-Driven Cancer Diagnostics, Personalized Metastatic Cancer Prognosis, Advanced Molecular Genetics in Cancer Care, AI-Driven Cancer Diagnostics, High-Accuracy Cancer Prognosis , Pharmaceutical Partnerships in Oncology, Targeted Cancer Therapy Insights, and AI Integration in Cancer Research